Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

Robert Wesolowski(The Ohio State University Wexner Medical Center), Bhuvaneswari Ramaswamy(The Ohio State University), Brandon Miller(The Ohio State University), Miguel A. Villalona‐Calero(University of California, Irvine), Michael V. Knopp(University of California, Los Angeles), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Alice P. Chen(National Institutes of Health), Daniel G. Stover(Harvard University), Michael R. Grever(The Ohio State University Wexner Medical Center), Charles L. Shapiro(Tisch Hospital), Priya Balasubramanian(Arc of the United States), Wenrui Duan(Dalian Medical University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Nathan C. Hall(McGill University), Susan Gillespie(The Ohio State University), Abigail B. Shoben(The Ohio State University), Jeffrey J. Chalmers(The Ohio State University), Meng Zhao(Zhengzhou University), Chadwick Wright(The Ohio State University), Joseph A. Sparano(Tisch Cancer Institute), Maryam B. Lustberg(Yale Cancer Center), Jun Zhang(OSF HealthCare), Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), A.A. Carey(The Ohio State University), Peter Amaya(The Ohio State University), Susan Geyer(University of South Florida), Eleni Andreopoulou(Cornell University)
The Oncologist
May 26, 2020
Cited by 14


Related Papers